PSY50 - ECONOMIC IMPACT OF ABOVE-LABEL DOSING WITH BIOLOGICS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS

Autor: Schwartzman, S., Tran, M., Li, Y., Zhou, H., Herrera, V., Palmer, J.B.
Zdroj: In Value in Health May 2016 19(3):A250-A250
Databáze: ScienceDirect